{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T05:32:36Z","timestamp":1775280756912,"version":"3.50.1"},"reference-count":215,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00210-025-04094-y","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T09:30:49Z","timestamp":1744191049000},"page":"11655-11682","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comprehensive insights into pancreatic cancer treatment approaches and cutting-edge nanocarrier solutions: from pathology to nanomedicine"],"prefix":"10.1007","volume":"398","author":[{"given":"Rohit","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sourabh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumari","family":"Komal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashmi","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shubham","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi Raj","family":"Pal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"4094_CR1","unstructured":"A Phase II Trial of Adebrelimab in Combination With NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer. (2024). https:\/\/clinicaltrials.gov\/study\/NCT06475326"},{"key":"4094_CR2","unstructured":"A Phase II Study of PEP02 as a Second Line Therapy for Patients With Metastatic Pancreatic Cancer. (2008). https:\/\/clinicaltrials.gov\/study\/NCT00813163"},{"key":"4094_CR3","unstructured":"A Phase III, Open-label, Randomized Study of the Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer. (2014). https:\/\/clinicaltrials.gov\/study\/NCT02043288"},{"key":"4094_CR4","unstructured":"Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety. (2024). https:\/\/clinicaltrials.gov\/study\/NCT06531278"},{"issue":"1","key":"4094_CR5","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1080\/10717544.2022.2086937","volume":"29","author":"A Aguilera-Garrido","year":"2022","unstructured":"Aguilera-Garrido A, Arranz E, Galvez-Ruiz MJ, Marchal JA, Galisteo-Gonzalez F, Giblin L (2022) Solid lipid nanoparticles to improve bioaccessibility and permeability of orally administered maslinic acid. Drug Deliv 29(1):1971\u20131982. https:\/\/doi.org\/10.1080\/10717544.2022.2086937","journal-title":"Drug Deliv"},{"key":"4094_CR6","doi-asserted-by":"publisher","unstructured":"Alavi M, Hamidi M (2019) Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles. Drug Metab Pers Ther, 34(1). https:\/\/doi.org\/10.1515\/dmpt-2018-0032","DOI":"10.1515\/dmpt-2018-0032"},{"issue":"6","key":"4094_CR7","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/pharmaceutics16060713","volume":"16","author":"A Alhussan","year":"2024","unstructured":"Alhussan A, Jackson N, Chow N, Gete E, Wretham N, Dos Santos N, Beckham W, Duzenli C, Chithrani DB (2024) In vitro and in vivo synergetic radiotherapy with gold nanoparticles and docetaxel for pancreatic cancer. Pharmaceutics 16(6):713. https:\/\/doi.org\/10.3390\/pharmaceutics16060713","journal-title":"Pharmaceutics"},{"issue":"1","key":"4094_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","volume":"65","author":"TM Allen","year":"2013","unstructured":"Allen TM, Cullis PR (2013) Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 65(1):36\u201348. https:\/\/doi.org\/10.1016\/j.addr.2012.09.037","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"4094_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s43094-024-00598-1","volume":"10","author":"TA Alotaibi","year":"2024","unstructured":"Alotaibi TA, Iyire A, Assaf S, Dahmash EZ (2024) Development and characterization of niosomes loaded mucoadhesive biodegradable ocular inserts for extended release of pilocarpine HCl. Future J Pharm Sci 10(1):22. https:\/\/doi.org\/10.1186\/s43094-024-00598-1","journal-title":"Future J Pharm Sci"},{"issue":"1","key":"4094_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/jso.27113","volume":"127","author":"Y Alwatari","year":"2023","unstructured":"Alwatari Y, Mosquera CM, Khoraki J, Rustom S, Wall N, Sevdalis AE, Stover W, Trevino JG, Kaplan B (2023) The impact of race\/ethnicity on pancreaticoduodenectomy outcomes for pancreatic cancer. J Surg Oncol 127(1):99\u2013108. https:\/\/doi.org\/10.1002\/jso.27113","journal-title":"J Surg Oncol"},{"issue":"1","key":"4094_CR11","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s43088-024-00566-x","volume":"13","author":"DM Anwar","year":"2024","unstructured":"Anwar DM, Hedeya HY, Ghozlan SH, Ewas BM, Khattab SN (2024) Surface-modified lipid-based nanocarriers as a pivotal delivery approach for cancer therapy: application and recent advances in targeted cancer treatment. Beni-Suef Univ J Basic Appl Sci 13(1):106. https:\/\/doi.org\/10.1186\/s43088-024-00566-x","journal-title":"Beni-Suef Univ J Basic Appl Sci"},{"issue":"11","key":"4094_CR12","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1021\/tx300166u","volume":"25","author":"T Asefa","year":"2012","unstructured":"Asefa T, Tao Z (2012) Biocompatibility of mesoporous silica nanoparticles. Chem Res Toxicol 25(11):2265\u20132284. https:\/\/doi.org\/10.1021\/tx300166u","journal-title":"Chem Res Toxicol"},{"issue":"8","key":"4094_CR13","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1111\/jphp.13098","volume":"71","author":"MF Attia","year":"2019","unstructured":"Attia MF, Anton N, Wallyn J, Omran Z, Vandamme TF (2019) An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. J Pharm Pharmacol 71(8):1185\u20131198. https:\/\/doi.org\/10.1111\/jphp.13098","journal-title":"J Pharm Pharmacol"},{"key":"4094_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-024-03193-6","author":"D Aydemir","year":"2024","unstructured":"Aydemir D, Ozturk K, Arslan FB, Calis S, Ulusu NN (2024) Gemcitabine-loaded chitosan nanoparticles enhanced apoptotic and ferroptotic response of gemcitabine treatment alone in the pancreatic cancer cells in vitro. Naunyn Schmiedebergs Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-024-03193-6","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"12","key":"4094_CR15","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1097\/PAS.0000000000000533","volume":"39","author":"O Basturk","year":"2015","unstructured":"Basturk O, Hong SM, Wood LD, Adsay NV, Albores-Saavedra J, Biankin AV, Brosens LA, Fukushima N, Goggins M, Hruban RH, Kato Y, Klimstra DS, Kloppel G, Krasinskas A, Longnecker DS, Matthaei H, Offerhaus GJ, Shimizu M, Takaori K, Baltimore Consensus M (2015) A revised classification system and recommendations from the baltimore consensus meeting for neoplastic precursor lesions in the pancreas. Am J Surg Pathol 39(12):1730\u20131741. https:\/\/doi.org\/10.1097\/PAS.0000000000000533","journal-title":"Am J Surg Pathol"},{"key":"4094_CR16","unstructured":"Bayever E, Dhindsa N, Fitzgerald Jonathan B, Laivins P, Moyo V, Niyikiza C (2016) Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan (US Patent No. US 2016\/0074382 A1). https:\/\/lens.org\/134-429-630-802-27X"},{"key":"4094_CR17","unstructured":"Bayever E, Dhindsa N, Fitzgerald Jonathan B, Laivins P, Moyo V, Niyikiza C, Kim J (2019) Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan (US Patent No. US 2019\/0117643 A1). https:\/\/lens.org\/043-479-537-384-882"},{"key":"4094_CR18","unstructured":"Bayever E, Dhindsa N, Fitzgerald Jonathan B, Laivins P, Moyo V, Niyikiza C, Kim J (2021) COMBINATIONS OF LIPOSOMAL IRINOTECAN, 5-FU AND LEUCOVORIN FOR THE TREATMENT OF PANCREATIC CANCER (EP Patent No. EP 3266456 B1). https:\/\/lens.org\/001-741-660-988-574"},{"issue":"3","key":"4094_CR19","doi-asserted-by":"publisher","first-page":"474","DOI":"10.3390\/nano9030474","volume":"9","author":"L Bayon-Cordero","year":"2019","unstructured":"Bayon-Cordero L, Alkorta I, Arana L (2019) Application of solid lipid nanoparticles to improve the efficiency of anticancer drugs. Nanomaterials (Basel) 9(3):474. https:\/\/doi.org\/10.3390\/nano9030474","journal-title":"Nanomaterials (Basel)"},{"issue":"6","key":"4094_CR20","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3892\/mco.2014.356","volume":"2","author":"R Bazak","year":"2014","unstructured":"Bazak R, Houri M, Achy SE, Hussein W, Refaat T (2014) Passive targeting of nanoparticles to cancer: a comprehensive review of the literature. Mol Clin Oncol 2(6):904\u2013908. https:\/\/doi.org\/10.3892\/mco.2014.356","journal-title":"Mol Clin Oncol"},{"key":"4094_CR21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.addr.2013.11.009","volume":"66","author":"N Bertrand","year":"2014","unstructured":"Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC (2014) Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 66:2\u201325. https:\/\/doi.org\/10.1016\/j.addr.2013.11.009","journal-title":"Adv Drug Deliv Rev"},{"issue":"11","key":"4094_CR22","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1158\/1535-7163.MCT-18-1011","volume":"18","author":"Y Bian","year":"2019","unstructured":"Bian Y, Teper Y, Mathews Griner LA, Aiken TJ, Shukla V, Guha R, Shinn P, Xin H-W, Pflicke H, Powers AS (2019) Target deconvolution of a multikinase inhibitor with antimetastatic properties identifies TAOK3 as a key contributor to a cancer stem cell\u2013like phenotype. Mol Cancer Ther 18(11):2097\u20132110","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"4094_CR23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/CJI.0000000000000127","volume":"39","author":"S Boudewijns","year":"2016","unstructured":"Boudewijns S, Westdorp H, Koornstra RH, Aarntzen EH, Schreibelt G, Creemers JH, Punt CJ, Figdor CG, de Vries IJ, Gerritsen WR, Bol KF (2016) Immune-related adverse events of dendritic cell vaccination correlate with immunologic and clinical outcome in stage III and IV melanoma patients. J Immunother 39(6):241\u2013248. https:\/\/doi.org\/10.1097\/CJI.0000000000000127","journal-title":"J Immunother"},{"issue":"3","key":"4094_CR24","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1038\/ctg.2016.18","volume":"7","author":"B Bournet","year":"2016","unstructured":"Bournet B, Muscari F, Buscail C, Assenat E, Barthet M, Hammel P, Selves J, Guimbaud R, Cordelier P, Buscail L (2016) KRAS G12D mutation subtype is a prognostic factor for advanced pancreatic adenocarcinoma. Clin Transl Gastroenterol 7(3):e157. https:\/\/doi.org\/10.1038\/ctg.2016.18","journal-title":"Clin Transl Gastroenterol"},{"key":"4094_CR25","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3389\/fvets.2020.00498","volume":"7","author":"R Canas-Arranz","year":"2020","unstructured":"Canas-Arranz R, de Leon P, Forner M, Defaus S, Bustos MJ, Torres E, Andreu D, Blanco E, Sobrino F (2020) Immunogenicity of a dendrimer B(2)T peptide harboring a T-Cell epitope from FMDV non-structural protein 3D. Front Vet Sci 7:498. https:\/\/doi.org\/10.3389\/fvets.2020.00498","journal-title":"Front Vet Sci"},{"key":"4094_CR26","unstructured":"Cao L, Jia S, Pu X (2020) Liposome nanoparticle chip, application of chip in preparing pancreatic cancer diagnosis products and corresponding marker (CN Patent No. CN 112048554 A). https:\/\/lens.org\/080-273-040-029-138"},{"issue":"1","key":"4094_CR27","doi-asserted-by":"publisher","first-page":"188318","DOI":"10.1016\/j.bbcan.2019.188318","volume":"1873","author":"J Carmicheal","year":"2020","unstructured":"Carmicheal J, Patel A, Dalal V, Atri P, Dhaliwal AS, Wittel UA, Malafa MP, Talmon G, Swanson BJ, Singh S, Jain M, Kaur S, Batra SK (2020) Elevating pancreatic cystic lesion stratification: current and future pancreatic cancer biomarker(s). Biochim Biophys Acta Rev Cancer 1873(1):188318. https:\/\/doi.org\/10.1016\/j.bbcan.2019.188318","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"4","key":"4094_CR28","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2217\/fon-2018-0607","volume":"15","author":"NA Carreau","year":"2019","unstructured":"Carreau NA, Pavlick AC (2019) Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma. Future Oncol 15(4):349\u2013358. https:\/\/doi.org\/10.2217\/fon-2018-0607","journal-title":"Future Oncol"},{"issue":"1","key":"4094_CR29","doi-asserted-by":"publisher","first-page":"9970665","DOI":"10.1049\/2024\/9970665","volume":"2024","author":"W Chen","year":"2024","unstructured":"Chen W, Liu H, Chen Y, Gao M (2024) Enhancement of therapeutic potential of oncolytic virus with homologous tumor cell membranes for pancreatic cancer. IET Nanobiotechnol 2024(1):9970665. https:\/\/doi.org\/10.1049\/2024\/9970665","journal-title":"IET Nanobiotechnol"},{"issue":"17","key":"4094_CR30","doi-asserted-by":"publisher","first-page":"3982","DOI":"10.3390\/molecules25173982","volume":"25","author":"AA Chis","year":"2020","unstructured":"Chis AA, Dobrea C, Morgovan C, Arseniu AM, Rus LL, Butuca A, Juncan AM, Totan M, Vonica-Tincu AL, Cormos G, Muntean AC, Muresan ML, Gligor FG, Frum A (2020) Applications and limitations of dendrimers in biomedicine. Molecules 25(17):3982. https:\/\/doi.org\/10.3390\/molecules25173982","journal-title":"Molecules"},{"issue":"33","key":"4094_CR31","doi-asserted-by":"publisher","first-page":"335103","DOI":"10.1088\/1361-6528\/ab9043","volume":"31","author":"Y Choi","year":"2020","unstructured":"Choi Y, Kim J, Yu S, Hong S (2020) pH- and temperature-responsive radially porous silica nanoparticles with high-capacity drug loading for controlled drug delivery. Nanotechnology 31(33):335103. https:\/\/doi.org\/10.1088\/1361-6528\/ab9043","journal-title":"Nanotechnology"},{"key":"4094_CR32","unstructured":"Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxanes-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer. (2023). https:\/\/clinicaltrials.gov\/study\/NCT06199895"},{"issue":"4","key":"4094_CR33","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1093\/jn\/nxz268","volume":"150","author":"SK Clinton","year":"2020","unstructured":"Clinton SK, Giovannucci EL, Hursting SD (2020) The World Cancer Research Fund\/American Institute for Cancer Research Third Expert Report on Diet, Nutrition, Physical Activity, and Cancer: Impact and Future Directions. J Nutr 150(4):663\u2013671. https:\/\/doi.org\/10.1093\/jn\/nxz268","journal-title":"J Nutr"},{"issue":"1","key":"4094_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.semradonc.2023.10.002","volume":"34","author":"LA Daamen","year":"2024","unstructured":"Daamen LA, Parikh PJ, Hall WA (2024) The use of MR-guided radiation therapy for pancreatic cancer. Semin Radiat Oncol 34(1):23\u201335. https:\/\/doi.org\/10.1016\/j.semradonc.2023.10.002","journal-title":"Semin Radiat Oncol"},{"issue":"7","key":"4094_CR35","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.3390\/medicina60071070","volume":"60","author":"S Dallavalle","year":"2024","unstructured":"Dallavalle S, Campagnoli G, Pastena P, Martinino A, Schiliro D, Giovinazzo F (2024) New frontiers in pancreatic cancer management: current treatment options and the emerging role of neoadjuvant therapy. Medicina (Kaunas) 60(7):1070. https:\/\/doi.org\/10.3390\/medicina60071070","journal-title":"Medicina (Kaunas)"},{"issue":"1","key":"4094_CR36","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1021\/cr030698+","volume":"104","author":"MC Daniel","year":"2004","unstructured":"Daniel MC, Astruc D (2004) Gold nanoparticles: assembly, supramolecular chemistry, quantum-size-related properties, and applications toward biology, catalysis, and nanotechnology. Chem Rev 104(1):293\u2013346. https:\/\/doi.org\/10.1021\/cr030698+","journal-title":"Chem Rev"},{"key":"4094_CR37","doi-asserted-by":"publisher","first-page":"102180","DOI":"10.1016\/j.ctrv.2021.102180","volume":"96","author":"S De Dosso","year":"2021","unstructured":"De Dosso S, Siebenhuner AR, Winder T, Meisel A, Fritsch R, Astaras C, Szturz P, Borner M (2021) Treatment landscape of metastatic pancreatic cancer. Cancer Treat Rev 96:102180. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102180","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"4094_CR38","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3390\/cancers15020416","volume":"15","author":"F Di Costanzo","year":"2023","unstructured":"Di Costanzo F, Di Costanzo F, Antonuzzo L, Mazza E, Giommoni E (2023) Optimizing first-line chemotherapy in metastatic pancreatic cancer: efficacy of FOLFIRINOX versus nab-paclitaxel plus gemcitabine. Cancers (Basel) 15(2):416. https:\/\/doi.org\/10.3390\/cancers15020416","journal-title":"Cancers (Basel)"},{"key":"4094_CR39","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.cis.2017.04.005","volume":"249","author":"R Diab","year":"2017","unstructured":"Diab R, Canilho N, Pavel IA, Haffner FB, Girardon M, Pasc A (2017) Silica-based systems for oral delivery of drugs, macromolecules and cells. Adv Colloid Interface Sci 249:346\u2013362. https:\/\/doi.org\/10.1016\/j.cis.2017.04.005","journal-title":"Adv Colloid Interface Sci"},{"issue":"11","key":"4094_CR40","doi-asserted-by":"publisher","first-page":"CD006053","DOI":"10.1002\/14651858.CD006053.pub5","volume":"11","author":"MK Diener","year":"2014","unstructured":"Diener MK, Fitzmaurice C, Schwarzer G, Seiler CM, Huttner FJ, Antes G, Knaebel HP, Buchler MW (2014) Pylorus-preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma. Cochrane Database Syst Rev 11(11):CD006053. https:\/\/doi.org\/10.1002\/14651858.CD006053.pub5","journal-title":"Cochrane Database Syst Rev"},{"key":"4094_CR41","doi-asserted-by":"publisher","first-page":"102509","DOI":"10.1016\/j.cis.2021.102509","volume":"296","author":"B Dutta","year":"2021","unstructured":"Dutta B, Barick KC, Hassan PA (2021) Recent advances in active targeting of nanomaterials for anticancer drug delivery. Adv Colloid Interface Sci 296:102509. https:\/\/doi.org\/10.1016\/j.cis.2021.102509","journal-title":"Adv Colloid Interface Sci"},{"issue":"21","key":"4094_CR42","doi-asserted-by":"publisher","first-page":"23737","DOI":"10.1021\/acsami.0c05308","volume":"12","author":"P Dwivedi","year":"2020","unstructured":"Dwivedi P, Kiran S, Han S, Dwivedi M, Khatik R, Fan R, Mangrio FA, Du K, Zhu Z, Yang C, Huang F, Ejaz A, Han R, Si T, Xu RX (2020) Magnetic targeting and ultrasound activation of liposome-microbubble conjugate for enhanced delivery of anticancer therapies. ACS Appl Mater Interfaces 12(21):23737\u201323751. https:\/\/doi.org\/10.1021\/acsami.0c05308","journal-title":"ACS Appl Mater Interfaces"},{"issue":"6","key":"4094_CR43","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1039\/c1cs15166e","volume":"41","author":"L Dykman","year":"2012","unstructured":"Dykman L, Khlebtsov N (2012) Gold nanoparticles in biomedical applications: recent advances and perspectives. Chem Soc Rev 41(6):2256\u20132282. https:\/\/doi.org\/10.1039\/c1cs15166e","journal-title":"Chem Soc Rev"},{"key":"4094_CR44","unstructured":"Efficacy and Safety of Irinotecan Liposome Injection Combined With Oxaliplatin and Tegafur (NASOX) in Adjuvant Chemotherapy for Pancreatic Cancer. (2024). https:\/\/clinicaltrials.gov\/study\/NCT06361316"},{"key":"4094_CR45","unstructured":"Eliel B, Sarah FB, Jonathan Basil F, Daniel FG, Bart SH, Ashish K, Helen LEE (2024) Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin (JP Patent No. JP 2024045587 A). https:\/\/lens.org\/078-457-588-773-119"},{"key":"4094_CR46","doi-asserted-by":"publisher","first-page":"129921","DOI":"10.1016\/j.colsurfa.2022.129921","volume":"654","author":"M Esmaeili Rad","year":"2022","unstructured":"Esmaeili Rad M, Egil AC, Ozaydin Ince G, Yuce M, Zarrabi A (2022) Optimization of curcumin loaded niosomes for drug delivery applications. Colloids Surf A 654:129921. https:\/\/doi.org\/10.1016\/j.colsurfa.2022.129921","journal-title":"Colloids Surf A"},{"issue":"38","key":"4094_CR47","doi-asserted-by":"publisher","first-page":"13833","DOI":"10.3748\/wjg.v20.i38.13833","volume":"20","author":"I Esposito","year":"2014","unstructured":"Esposito I, Konukiewitz B, Schlitter AM, Kloppel G (2014) Pathology of pancreatic ductal adenocarcinoma: facts, challenges and future developments. World J Gastroenterol 20(38):13833\u201313841. https:\/\/doi.org\/10.3748\/wjg.v20.i38.13833","journal-title":"World J Gastroenterol"},{"issue":"5","key":"4094_CR48","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1136\/gutjnl-2018-316027","volume":"67","author":"European Study Group on Cystic Tumours of the P","year":"2018","unstructured":"European Study Group on Cystic Tumours of the P (2018) European evidence-based guidelines on pancreatic cystic neoplasms. Gut 67(5):789\u2013804. https:\/\/doi.org\/10.1136\/gutjnl-2018-316027","journal-title":"Gut"},{"issue":"1","key":"4094_CR49","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-024-01561-6","volume":"17","author":"P Farhangnia","year":"2024","unstructured":"Farhangnia P, Khorramdelazad H, Nickho H, Delbandi AA (2024) Current and future immunotherapeutic approaches in pancreatic cancer treatment. J Hematol Oncol 17(1):40. https:\/\/doi.org\/10.1186\/s13045-024-01561-6","journal-title":"J Hematol Oncol"},{"key":"4094_CR50","doi-asserted-by":"publisher","first-page":"102647","DOI":"10.1016\/j.jddst.2021.102647","volume":"64","author":"G Fernandes","year":"2021","unstructured":"Fernandes G, Pandey A, Kulkarni S, Mutalik SP, Nikam AN, Seetharam RN, Kulkarni SS, Mutalik S (2021) Supramolecular dendrimers based novel platforms for effective oral delivery of therapeutic moieties. J Drug Deliv Sci Technol 64:102647. https:\/\/doi.org\/10.1016\/j.jddst.2021.102647","journal-title":"J Drug Deliv Sci Technol"},{"issue":"1","key":"4094_CR51","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12935-024-03219-2","volume":"24","author":"A Firouzi Amandi","year":"2024","unstructured":"Firouzi Amandi A, Bahmanyar Z, Dadashpour M, Lak M, Natami M, Dogus Y, Alem M, Adeli OA (2024) Fabrication of magnetic niosomal platform for delivery of resveratrol: potential anticancer activity against human pancreatic cancer Capan-1 cell. Cancer Cell Int 24(1):46. https:\/\/doi.org\/10.1186\/s12935-024-03219-2","journal-title":"Cancer Cell Int"},{"key":"4094_CR52","doi-asserted-by":"crossref","unstructured":"Fujita I, Hatori T, Fukuda A, Onizawa S, Sugiki T, Furukawa T, Kawamura S, Shiratori K, Yamamoto M (2006) Early histological findings of mucinous cystic neoplasm of the pancreas (MCN): a case report. Pancreas, 33(4):461\u2013462. https:\/\/journals.lww.com\/pancreasjournal\/fulltext\/2006\/11000\/early_histological_findings_of_mucinous_cystic.86.aspx","DOI":"10.1097\/00006676-200611000-00086"},{"issue":"2","key":"4094_CR53","doi-asserted-by":"publisher","first-page":"210","DOI":"10.20524\/aog.2020.0450","volume":"33","author":"M Gad","year":"2020","unstructured":"Gad M (2020) Temporal trends of incidence and mortality in Asian-Americans with pancreatic adenocarcinoma: an epidemiological study. Annals Gastroenterol 33(2):210\u2013218. https:\/\/doi.org\/10.20524\/aog.2020.0450","journal-title":"Annals Gastroenterol"},{"key":"4094_CR54","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jconrel.2021.02.016","volume":"332","author":"B Ghosh","year":"2021","unstructured":"Ghosh B, Biswas S (2021) Polymeric micelles in cancer therapy: State of the art. J Control Release 332:127\u2013147. https:\/\/doi.org\/10.1016\/j.jconrel.2021.02.016","journal-title":"J Control Release"},{"issue":"4","key":"4094_CR55","doi-asserted-by":"publisher","first-page":"e1000267","DOI":"10.1371\/journal.pmed.1000267","volume":"7","author":"S Gillen","year":"2010","unstructured":"Gillen S, Schuster T, Meyer ZumBuschenfelde C, Friess H, Kleeff J (2010) Preoperative\/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7(4):e1000267. https:\/\/doi.org\/10.1371\/journal.pmed.1000267","journal-title":"PLoS Med"},{"issue":"12","key":"4094_CR56","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1634\/theoncologist.2010-0151","volume":"15","author":"R Grutzmann","year":"2010","unstructured":"Grutzmann R, Niedergethmann M, Pilarsky C, Kloppel G, Saeger HD (2010) Intraductal papillary mucinous tumors of the pancreas: biology, diagnosis, and treatment. Oncologist 15(12):1294\u20131309. https:\/\/doi.org\/10.1634\/theoncologist.2010-0151","journal-title":"Oncologist"},{"key":"4094_CR57","doi-asserted-by":"publisher","unstructured":"Gul, S., Azad, S. A., Saleem, K., & Ilyas, U. (2023). Development of self-nano-emulsifying drug delivery system for gemcitabine: in vitro and ex vivo evaluation. Pharmaceut Commun 2(2). https:\/\/doi.org\/10.55627\/pharma.002.02.0574","DOI":"10.55627\/pharma.002.02.0574"},{"issue":"9","key":"4094_CR58","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.3109\/00365521.2015.1024281","volume":"50","author":"C Gundewar","year":"2015","unstructured":"Gundewar C, Sasor A, Hilmersson KS, Andersson R, Ansari D (2015) The role of SPARC expression in pancreatic cancer progression and patient survival. Scand J Gastroenterol 50(9):1170\u20131174. https:\/\/doi.org\/10.3109\/00365521.2015.1024281","journal-title":"Scand J Gastroenterol"},{"key":"4094_CR59","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.16686","author":"JR Habib","year":"2024","unstructured":"Habib JR, Rompen IF, Javed AA, Grewal M, Kinny-Koster B, Andel PCM, Hewitt DB, Sacks GD, Besselink MG, van Santvoort HC, Daamen LA, Loos M, He J, Buchler MW, Wolfgang CL, Molenaar IQ (2024) Outcomes in intraductal papillary mucinous neoplasm-derived pancreatic cancer differ from PanIN-derived pancreatic cancer. J Gastroenterol Hepatol. https:\/\/doi.org\/10.1111\/jgh.16686","journal-title":"J Gastroenterol Hepatol"},{"key":"4094_CR60","doi-asserted-by":"crossref","unstructured":"He Q, Liu Z, Wang J (2022) Targeting KRAS in PDAC: a new way to cure it? Cancers 14(20):4982. https:\/\/www.mdpi.com\/2072-6694\/14\/20\/4982","DOI":"10.3390\/cancers14204982"},{"issue":"15","key":"4094_CR61","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.3390\/polym14153139","volume":"14","author":"Y Herdiana","year":"2022","unstructured":"Herdiana Y, Wathoni N, Shamsuddin S, Muchtaridi M (2022) Cytotoxicity enhancement in MCF-7 breast cancer cells with depolymerized chitosan delivery of alpha-mangostin. Polym (Basel) 14(15):3139. https:\/\/doi.org\/10.3390\/polym14153139","journal-title":"Polym (Basel)"},{"key":"4094_CR62","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.msec.2019.01.129","volume":"99","author":"TT Hoang Thi","year":"2019","unstructured":"Hoang Thi TT, Cao VD, Nguyen TNQ, Hoang DT, Ngo VC, Nguyen DH (2019) Functionalized mesoporous silica nanoparticles and biomedical applications. Mater Sci Eng C Mater Biol Appl 99:631\u2013656. https:\/\/doi.org\/10.1016\/j.msec.2019.01.129","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"issue":"5","key":"4094_CR63","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/00000478-200105000-00003","volume":"25","author":"RH Hruban","year":"2001","unstructured":"Hruban RH, Adsay NV, Albores-Saavedra J, Compton C, Garrett ES, Goodman SN, Kern SE, Klimstra DS, Kloppel G, Longnecker DS, Luttges J, Offerhaus GJ (2001) Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 25(5):579\u2013586. https:\/\/doi.org\/10.1097\/00000478-200105000-00003","journal-title":"Am J Surg Pathol"},{"key":"4094_CR64","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.yasu.2010.05.011","volume":"44","author":"RH Hruban","year":"2010","unstructured":"Hruban RH, Canto MI, Goggins M, Schulick R, Klein AP (2010) Update on familial pancreatic cancer. Adv Surg 44:293\u2013311. https:\/\/doi.org\/10.1016\/j.yasu.2010.05.011","journal-title":"Adv Surg"},{"issue":"27","key":"4094_CR65","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.3748\/wjg.v27.i27.4298","volume":"27","author":"JX Hu","year":"2021","unstructured":"Hu JX, Zhao CF, Chen WB, Liu QC, Li QW, Lin YY, Gao F (2021) Pancreatic cancer: a review of epidemiology, trend, and risk factors. World J Gastroenterol 27(27):4298\u20134321. https:\/\/doi.org\/10.3748\/wjg.v27.i27.4298","journal-title":"World J Gastroenterol"},{"issue":"8","key":"4094_CR66","doi-asserted-by":"publisher","first-page":"267","DOI":"10.15698\/cst2019.08.195","volume":"3","author":"Y Huai","year":"2019","unstructured":"Huai Y, Zhang Y, Xiong X, Das S, Bhattacharya R, Mukherjee P (2019) Gold Nanoparticles sensitize pancreatic cancer cells to gemcitabine. Cell Stress 3(8):267\u2013279. https:\/\/doi.org\/10.15698\/cst2019.08.195","journal-title":"Cell Stress"},{"issue":"3","key":"4094_CR67","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jconrel.2011.06.004","volume":"155","author":"H-C Huang","year":"2011","unstructured":"Huang H-C, Barua S, Sharma G, Dey SK, Rege K (2011) Inorganic nanoparticles for cancer imaging and therapy. J Control Release 155(3):344\u2013357","journal-title":"J Control Release"},{"key":"4094_CR68","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejpb.2021.11.005","volume":"170","author":"S Huang","year":"2022","unstructured":"Huang S, Huang X, Yan H (2022) Peptide dendrimers as potentiators of conventional chemotherapy in the treatment of pancreatic cancer in a mouse model. Eur J Pharm Biopharm 170:121\u2013132. https:\/\/doi.org\/10.1016\/j.ejpb.2021.11.005","journal-title":"Eur J Pharm Biopharm"},{"key":"4094_CR69","doi-asserted-by":"publisher","first-page":"102018","DOI":"10.1016\/j.jddst.2020.102018","volume":"60","author":"S Huda","year":"2020","unstructured":"Huda S, Alam MA, Sharma PK (2020) Smart nanocarriers-based drug delivery for cancer therapy: an innovative and developing strategy. J Drug Deliv Sci Technol 60:102018. https:\/\/doi.org\/10.1016\/j.jddst.2020.102018","journal-title":"J Drug Deliv Sci Technol"},{"issue":"9","key":"4094_CR70","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1158\/1541-7786.MCR-15-0203","volume":"13","author":"JC Hunter","year":"2015","unstructured":"Hunter JC, Manandhar A, Carrasco MA, Gurbani D, Gondi S, Westover KD (2015) Biochemical and structural analysis of common cancer-associated KRAS mutations. Mol Cancer Res 13(9):1325\u20131335. https:\/\/doi.org\/10.1158\/1541-7786.MCR-15-0203","journal-title":"Mol Cancer Res"},{"issue":"2","key":"4094_CR71","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s12668-025-01873-y","volume":"15","author":"MS Hussain","year":"2025","unstructured":"Hussain MS, Prajapati BG, Gandhi SM, Sharma M, Kapoor DU, Elossaily GM, Garg S (2025) Overcoming obstacles: the role of lipid nanocarriers in therapeutic approaches for pancreatic cancer. BioNanoScience 15(2):262. https:\/\/doi.org\/10.1007\/s12668-025-01873-y","journal-title":"BioNanoScience"},{"issue":"11","key":"4094_CR72","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1038\/sj.bjc.6602619","volume":"92","author":"R Huxley","year":"2005","unstructured":"Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M (2005) Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 92(11):2076\u20132083. https:\/\/doi.org\/10.1038\/sj.bjc.6602619","journal-title":"Br J Cancer"},{"issue":"5","key":"4094_CR73","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.3390\/nano11051215","volume":"11","author":"KH Huynh","year":"2021","unstructured":"Huynh KH, Hahm E, Noh MS, Lee JH, Pham XH, Lee SH, Kim J, Rho WY, Chang H, Kim DM, Baek A, Kim DE, Jeong DH, Park SM, Jun BH (2021) Recent advances in surface-enhanced Raman scattering magnetic plasmonic particles for bioapplications. Nanomaterials (Basel) 11(5):1215. https:\/\/doi.org\/10.3390\/nano11051215","journal-title":"Nanomaterials (Basel)"},{"key":"4094_CR74","unstructured":"Irinotecan Liposome II in Combination With 5-FU\/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer: A Prospective, Single-arm, Multicenter, Phase II Study. (2024). https:\/\/clinicaltrials.gov\/study\/NCT06387810"},{"key":"4094_CR75","doi-asserted-by":"publisher","first-page":"121852","DOI":"10.1016\/j.ijpharm.2022.121852","volume":"622","author":"S Jain","year":"2022","unstructured":"Jain S, Dongare K, Nallamothu B, Parkash Dora C, Kushwah V, Katiyar SS, Sharma R (2022) Enhanced stability and oral bioavailability of erlotinib by solid self nano emulsifying drug delivery systems. Int J Pharm 622:121852. https:\/\/doi.org\/10.1016\/j.ijpharm.2022.121852","journal-title":"Int J Pharm"},{"issue":"12","key":"4094_CR76","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/s41578-021-00385-x","volume":"6","author":"TI Janjua","year":"2021","unstructured":"Janjua TI, Cao Y, Yu C, Popat A (2021) Clinical translation of silica nanoparticles. Nat Rev Mater 6(12):1072\u20131074. https:\/\/doi.org\/10.1038\/s41578-021-00385-x","journal-title":"Nat Rev Mater"},{"issue":"1","key":"4094_CR77","doi-asserted-by":"publisher","first-page":"01","DOI":"10.32350\/cpr.21.01","volume":"2","author":"S Javaid","year":"2024","unstructured":"Javaid S, Rana T, Naeem Z, Sajid N (2024) Exploring niosomes: a comprehensive review of their structure, formulation, and biomedical applications. Curr Pharmaceut Res 2(1):01\u201334. https:\/\/doi.org\/10.32350\/cpr.21.01","journal-title":"Curr Pharmaceut Res"},{"issue":"3 Pt 2","key":"4094_CR78","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.lpm.2019.02.027","volume":"48","author":"F Jeune","year":"2019","unstructured":"Jeune F, Coriat R, Prat F, Dousset B, Vaillant JC, Gaujoux S (2019) Pancreatic cancer surgical management. Presse Med 48(3 Pt 2):e147\u2013e158. https:\/\/doi.org\/10.1016\/j.lpm.2019.02.027","journal-title":"Presse Med"},{"key":"4094_CR79","doi-asserted-by":"publisher","unstructured":"Jiang W, Liang M, Lei Q, Li G, Wu S (2023) The current status of photodynamic therapy in cancer treatment. Cancers (Basel) 15(3). https:\/\/doi.org\/10.3390\/cancers15030585","DOI":"10.3390\/cancers15030585"},{"issue":"18","key":"4094_CR80","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.7150\/ijms.49801","volume":"17","author":"C Jin","year":"2020","unstructured":"Jin C, Wang K, Oppong-Gyebi A, Hu J (2020) Application of nanotechnology in cancer diagnosis and therapy - a mini-review. Int J Med Sci 17(18):2964\u20132973. https:\/\/doi.org\/10.7150\/ijms.49801","journal-title":"Int J Med Sci"},{"issue":"2","key":"4094_CR81","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1517\/17425240903427940","volume":"7","author":"T Kaasgaard","year":"2010","unstructured":"Kaasgaard T, Andresen TL (2010) Liposomal cancer therapy: exploiting tumor characteristics. Expert Opin Drug Deliv 7(2):225\u2013243. https:\/\/doi.org\/10.1517\/17425240903427940","journal-title":"Expert Opin Drug Deliv"},{"issue":"6","key":"4094_CR82","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.ejso.2021.12.009","volume":"48","author":"J Kaiser","year":"2022","unstructured":"Kaiser J, Scheifele C, Hinz U, Leonhardt CS, Hank T, Koenig AK, Tjaden C, Hackert T, Bergmann F, Buchler MW, Strobel O (2022) IPMN-associated pancreatic cancer: survival, prognostic staging and impact of adjuvant chemotherapy. Eur J Surg Oncol 48(6):1309\u20131320. https:\/\/doi.org\/10.1016\/j.ejso.2021.12.009","journal-title":"Eur J Surg Oncol"},{"key":"4094_CR83","doi-asserted-by":"publisher","first-page":"116816","DOI":"10.1016\/j.mseb.2023.116816","volume":"297","author":"S Kandula","year":"2023","unstructured":"Kandula S, Singh PK, Kaur GA, Tiwari A (2023) Trends in smart drug delivery systems for targeting cancer cells. Mater Sci Eng, B 297:116816","journal-title":"Mater Sci Eng, B"},{"issue":"2","key":"4094_CR84","first-page":"21","volume":"2","author":"HS Kapare","year":"2020","unstructured":"Kapare HS, Metkar SR (2020) Micellar drug delivery system: a review. Pharmaceutical Resonance 2(2):21\u201326","journal-title":"Pharmaceutical Resonance"},{"issue":"6","key":"4094_CR85","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.3390\/jcm10061284","volume":"10","author":"MG Keane","year":"2021","unstructured":"Keane MG, Afghani E (2021) A review of the diagnosis and management of premalignant pancreatic cystic lesions. J Clin Med 10(6):1284. https:\/\/doi.org\/10.3390\/jcm10061284","journal-title":"J Clin Med"},{"issue":"10","key":"4094_CR86","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1517\/17425247.2012.719870","volume":"9","author":"AW Khan","year":"2012","unstructured":"Khan AW, Kotta S, Ansari SH, Sharma RK, Ali J (2012) Potentials and challenges in self-nanoemulsifying drug delivery systems. Expert Opin Drug Deliv 9(10):1305\u20131317. https:\/\/doi.org\/10.1517\/17425247.2012.719870","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"4094_CR87","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.pan.2021.11.005","volume":"22","author":"A Khan","year":"2022","unstructured":"Khan A, Vege SS, Dudeja V, Chari ST (2022) Staging exocrine pancreatic dysfunction. Pancreatology 22(1):168\u2013172. https:\/\/doi.org\/10.1016\/j.pan.2021.11.005","journal-title":"Pancreatology"},{"issue":"10","key":"4094_CR88","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1159\/000493554","volume":"41","author":"JY Kim","year":"2018","unstructured":"Kim JY, Hong SM (2018) Precursor lesions of pancreatic cancer. Oncol Res Treat 41(10):603\u2013610. https:\/\/doi.org\/10.1159\/000493554","journal-title":"Oncol Res Treat"},{"issue":"1","key":"4094_CR89","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s41747-024-00436-2","volume":"8","author":"S Kim","year":"2024","unstructured":"Kim S, Lee JY, Park EJ, Ahn YD, Cheon Y, Sim W, Lee HJ (2024) Tumor suppression effect of ultrasound-sensitive nanoparticles with focused ultrasound in a pancreas cancer xenograft model. Eur Radiol Exp 8(1):39. https:\/\/doi.org\/10.1186\/s41747-024-00436-2","journal-title":"Eur Radiol Exp"},{"key":"4094_CR90","doi-asserted-by":"publisher","unstructured":"Klotz R, Hackert T, B\u00fcchler MW (2023) Natural history of cystic neoplasms. In The Pancreas (pp. 666\u2013673). https:\/\/doi.org\/10.1002\/9781119876007.ch86","DOI":"10.1002\/9781119876007.ch86"},{"key":"4094_CR91","doi-asserted-by":"publisher","first-page":"101148","DOI":"10.1016\/j.nanoso.2024.101148","volume":"38","author":"A Kumar","year":"2024","unstructured":"Kumar A, Jayeoye TJ, Mohite P, Singh S, Rajput T, Munde S, Eze FN, Chidrawar VR, Puri A, Prajapati BG, Parihar A (2024) Sustainable and consumer-centric nanotechnology-based materials: an update on the multifaceted applications, risks and tremendous opportunities. Nano-Structures Nano-Objects 38:101148. https:\/\/doi.org\/10.1016\/j.nanoso.2024.101148","journal-title":"Nano-Structures Nano-Objects"},{"issue":"3","key":"4094_CR92","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3109\/1061186X.2015.1051049","volume":"24","author":"P Kumari","year":"2016","unstructured":"Kumari P, Ghosh B, Biswas S (2016) Nanocarriers for cancer-targeted drug delivery. J Drug Target 24(3):179\u2013191. https:\/\/doi.org\/10.3109\/1061186X.2015.1051049","journal-title":"J Drug Target"},{"key":"4094_CR93","doi-asserted-by":"publisher","unstructured":"Kurokawa H, Taninaka A, Yoshitomi T, Shigekawa H, Matsui H (2022) Near-infrared light irradiation of porphyrin-modified gold nanoparticles promotes cancer-cell-specific cytotoxicity. Molecules 27(4). https:\/\/doi.org\/10.3390\/molecules27041238","DOI":"10.3390\/molecules27041238"},{"issue":"3","key":"4094_CR94","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s11938-018-0190-2","volume":"16","author":"I Levink","year":"2018","unstructured":"Levink I, Bruno MJ, Cahen DL (2018) Management of intraductal papillary mucinous neoplasms: controversies in guidelines and future perspectives. Curr Treat Options Gastroenterol 16(3):316\u2013332. https:\/\/doi.org\/10.1007\/s11938-018-0190-2","journal-title":"Curr Treat Options Gastroenterol"},{"issue":"11","key":"4094_CR95","doi-asserted-by":"publisher","first-page":"907","DOI":"10.5306\/wjco.v13.i11.907","volume":"13","author":"D Lew","year":"2022","unstructured":"Lew D, Kamal F, Phan K, Randhawa K, Cornwell S, Bangolo AI, Weissman S, Pandol SJ (2022) Epidemiologic risk factors for patients admitted with chronic pancreatitis and pancreatic ductal adenocarcinoma in the United States. World J Clin Oncol 13(11):907\u2013917. https:\/\/doi.org\/10.5306\/wjco.v13.i11.907","journal-title":"World J Clin Oncol"},{"issue":"2","key":"4094_CR96","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10552-010-9686-3","volume":"22","author":"D Li","year":"2011","unstructured":"Li D, Tang H, Hassan MM, Holly EA, Bracci PM, Silverman DT (2011) Diabetes and risk of pancreatic cancer: a pooled analysis of three large case-control studies. Cancer Causes Control 22(2):189\u2013197. https:\/\/doi.org\/10.1007\/s10552-010-9686-3","journal-title":"Cancer Causes Control"},{"issue":"1","key":"4094_CR97","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12885-025-13597-z","volume":"25","author":"T Li","year":"2025","unstructured":"Li T, Lin C, Wang W (2025) Global, regional, and national burden of pancreatic cancer from 1990 to 2021, its attributable risk factors, and projections to 2050: a systematic analysis of the global burden of disease study 2021. BMC Cancer 25(1):189. https:\/\/doi.org\/10.1186\/s12885-025-13597-z","journal-title":"BMC Cancer"},{"key":"4094_CR98","unstructured":"Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil\/Calcium Folinate in Combination With Camrelizumab for Borderline Resectable Pancreatic Cancer: a Prospective, Exploratory Study (2024). https:\/\/clinicaltrials.gov\/study\/NCT06345300"},{"issue":"1","key":"4094_CR99","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/EXP.20210003","volume":"1","author":"J Liu","year":"2021","unstructured":"Liu J, Chen C, Wei T, Gayet O, Loncle C, Borge L, Dusetti N, Ma X, Marson D, Laurini E, Pricl S, Gu Z, Iovanna J, Peng L, Liang XJ (2021a) Dendrimeric nanosystem consistently circumvents heterogeneous drug response and resistance in pancreatic cancer. Exploration (Beijing) 1(1):21\u201334. https:\/\/doi.org\/10.1002\/EXP.20210003","journal-title":"Exploration (Beijing)"},{"issue":"6","key":"4094_CR100","doi-asserted-by":"publisher","first-page":"2002147","DOI":"10.1002\/advs.202002147","volume":"8","author":"X Liu","year":"2021","unstructured":"Liu X, Jiang J, Liao YP, Tang I, Zheng E, Qiu W, Lin M, Wang X, Ji Y, Mei KC, Liu Q, Chang CH, Wainberg ZA, Nel AE, Meng H (2021b) Combination chemo-immunotherapy for pancreatic cancer using the immunogenic effects of an irinotecan silicasome nanocarrier plus anti-PD-1. Adv Sci (Weinh) 8(6):2002147. https:\/\/doi.org\/10.1002\/advs.202002147","journal-title":"Adv Sci (Weinh)"},{"issue":"3","key":"4094_CR101","doi-asserted-by":"publisher","first-page":"675","DOI":"10.3390\/molecules29030675","volume":"29","author":"D Liu","year":"2024","unstructured":"Liu D, Wang L, Li H, Li D, Zhou J, Wang J, Zhang Q, Cai D (2024) Co-delivery of gemcitabine and honokiol by lipid bilayer-coated mesoporous silica nanoparticles enhances pancreatic cancer therapy via targeting depletion of tumor stroma. Molecules 29(3):675. https:\/\/doi.org\/10.3390\/molecules29030675","journal-title":"Molecules"},{"issue":"31","key":"4094_CR102","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1200\/JCO.2011.34.8904","volume":"29","author":"PJ Loehrer Sr","year":"2011","unstructured":"Loehrer PJ Sr, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, Flynn P, Ramanathan RK, Crane CH, Alberts SR, Benson AB 3rd (2011) Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 29(31):4105\u20134112. https:\/\/doi.org\/10.1200\/JCO.2011.34.8904","journal-title":"J Clin Oncol"},{"key":"4094_CR103","doi-asserted-by":"publisher","first-page":"6313","DOI":"10.2147\/IJN.S279192","volume":"16","author":"T Lu","year":"2021","unstructured":"Lu T, Prakash J (2021) Nanomedicine strategies to enhance tumor drug penetration in pancreatic cancer. Int J Nanomedicine 16:6313\u20136328. https:\/\/doi.org\/10.2147\/IJN.S279192","journal-title":"Int J Nanomedicine"},{"issue":"4","key":"4094_CR104","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.path.2016.05.003","volume":"9","author":"C Luchini","year":"2016","unstructured":"Luchini C, Capelli P, Scarpa A (2016) Pancreatic ductal adenocarcinoma and its variants. Surg Pathol Clin 9(4):547\u2013560. https:\/\/doi.org\/10.1016\/j.path.2016.05.003","journal-title":"Surg Pathol Clin"},{"key":"4094_CR105","doi-asserted-by":"publisher","first-page":"216979","DOI":"10.1016\/j.canlet.2024.216979","volume":"594","author":"W Luo","year":"2024","unstructured":"Luo W, Zhang T (2024) The new era of pancreatic cancer treatment: application of nanotechnology breaking through bottlenecks. Cancer Lett 594:216979","journal-title":"Cancer Lett"},{"issue":"2","key":"4094_CR106","doi-asserted-by":"publisher","first-page":"216","DOI":"10.21147\/j.issn.1000-9604.2021.02.09","volume":"33","author":"W Luo","year":"2021","unstructured":"Luo W, Qiu J, Zheng L, Zhang T (2021) Novel therapies targeting hypoxia mechanism to treat pancreatic cancer. Chin J Cancer Res 33(2):216\u2013231. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2021.02.09","journal-title":"Chin J Cancer Res"},{"issue":"18","key":"4094_CR107","doi-asserted-by":"publisher","first-page":"11653","DOI":"10.1021\/acs.chemrev.0c00963","volume":"121","author":"S Lv","year":"2021","unstructured":"Lv S, Sylvestre M, Prossnitz AN, Yang LF, Pun SH (2021) Design of polymeric carriers for intracellular peptide delivery in oncology applications. Chem Rev 121(18):11653\u201311698. https:\/\/doi.org\/10.1021\/acs.chemrev.0c00963","journal-title":"Chem Rev"},{"issue":"42","key":"4094_CR108","doi-asserted-by":"publisher","first-page":"49614","DOI":"10.1021\/acsami.1c09379","volume":"13","author":"WM MacCuaig","year":"2021","unstructured":"MacCuaig WM, Fouts BL, McNally MW, Grizzle WE, Chuong P, Samykutty A, Mukherjee P, Li M, Jasinski JB, Behkam B, McNally LR (2021) Active targeting significantly outperforms nanoparticle size in facilitating tumor-specific uptake in orthotopic pancreatic cancer. ACS Appl Mater Interfaces 13(42):49614\u201349630. https:\/\/doi.org\/10.1021\/acsami.1c09379","journal-title":"ACS Appl Mater Interfaces"},{"issue":"1","key":"4094_CR109","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/14656566.2024.2304125","volume":"25","author":"H Mahadevia","year":"2024","unstructured":"Mahadevia H, Uson Junior PLS, Wang J, Borad M, Babiker H (2024) An overview of up-and-coming immune checkpoint inhibitors for pancreatic cancer. Expert Opin Pharmacother 25(1):79\u201390. https:\/\/doi.org\/10.1080\/14656566.2024.2304125","journal-title":"Expert Opin Pharmacother"},{"issue":"9","key":"4094_CR110","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1093\/bjs\/znab131","volume":"108","author":"G Marchegiani","year":"2021","unstructured":"Marchegiani G, Andrianello S, Crippa S, Pollini T, Belfiori G, Gozzini L, Cassalia F, Caravati A, Luchini C, Doglioni C (2021) Actual malignancy risk of either operated or non-operated presumed mucinous cystic neoplasms of the pancreas under surveillance. Br J Surg 108(9):1097\u20131104","journal-title":"Br J Surg"},{"key":"4094_CR111","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.cis.2013.11.018","volume":"205","author":"C Marianecci","year":"2014","unstructured":"Marianecci C, Di Marzio L, Rinaldi F, Celia C, Paolino D, Alhaique F, Esposito S, Carafa M (2014) Niosomes from 80s to present: the state of the art. Adv Colloid Interface Sci 205:187\u2013206. https:\/\/doi.org\/10.1016\/j.cis.2013.11.018","journal-title":"Adv Colloid Interface Sci"},{"issue":"12","key":"4094_CR112","doi-asserted-by":"publisher","first-page":"9946","DOI":"10.3390\/ijms24129946","volume":"24","author":"L Marstrand-Dauce","year":"2023","unstructured":"Marstrand-Dauce L, Lorenzo D, Chassac A, Nicole P, Couvelard A, Haumaitre C (2023) Acinar-to-ductal metaplasia (ADM): on the road to pancreatic intraepithelial neoplasia (PanIN) and pancreatic cancer. Int J Mol Sci 24(12):9946. https:\/\/doi.org\/10.3390\/ijms24129946","journal-title":"Int J Mol Sci"},{"issue":"1137","key":"4094_CR113","doi-asserted-by":"publisher","first-page":"20220072","DOI":"10.1259\/bjr.20220072","volume":"95","author":"L Marti-Bonmati","year":"2022","unstructured":"Marti-Bonmati L, Cerda-Alberich L, Perez-Girbes A, Diaz Beveridge R, Montalva Oron E, Perez Rojas J, Alberich-Bayarri A (2022) Pancreatic cancer, radiomics and artificial intelligence. Br J Radiol 95(1137):20220072. https:\/\/doi.org\/10.1259\/bjr.20220072","journal-title":"Br J Radiol"},{"issue":"3","key":"4094_CR114","doi-asserted-by":"publisher","first-page":"146","DOI":"10.15171\/mejdd.2017.65","volume":"9","author":"S Masoudi","year":"2017","unstructured":"Masoudi S, MomayezSanat Z, Mahmud Saleh A, Nozari N, Ghamarzad N, Pourshams A (2017) Menstrual and reproductive factors and risk of pancreatic cancer in women. Middle East J Dig Dis 9(3):146\u2013149. https:\/\/doi.org\/10.15171\/mejdd.2017.65","journal-title":"Middle East J Dig Dis"},{"issue":"43","key":"4094_CR115","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","volume":"24","author":"A McGuigan","year":"2018","unstructured":"McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS (2018) Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol 24(43):4846\u20134861. https:\/\/doi.org\/10.3748\/wjg.v24.i43.4846","journal-title":"World J Gastroenterol"},{"issue":"5","key":"4094_CR116","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.bpg.2017.09.015","volume":"31","author":"UC McMenamin","year":"2017","unstructured":"McMenamin UC, McCain S, Kunzmann AT (2017) Do smoking and alcohol behaviours influence GI cancer survival? Best Pract Res Clin Gastroenterol 31(5):569\u2013577. https:\/\/doi.org\/10.1016\/j.bpg.2017.09.015","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"4094_CR117","doi-asserted-by":"publisher","first-page":"102555","DOI":"10.1016\/j.jddst.2021.102555","volume":"64","author":"S Md","year":"2021","unstructured":"Md S, Alhakamy NA, Aldawsari HM, Ahmad J, Alharbi WS, Asfour HZ (2021) Resveratrol loaded self-nanoemulsifying drug delivery system (SNEDDS) for pancreatic cancer: formulation design, optimization and in vitro evaluation. J Drug Deliv Sci Technol 64:102555. https:\/\/doi.org\/10.1016\/j.jddst.2021.102555","journal-title":"J Drug Deliv Sci Technol"},{"issue":"6","key":"4094_CR118","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.pan.2017.09.002","volume":"17","author":"R Memba","year":"2017","unstructured":"Memba R, Duggan SN, Ni Chonchubhair HM, Griffin OM, Bashir Y, O\u2019Connor DB, Murphy A, McMahon J, Volcov Y, Ryan BM, Conlon KC (2017) The potential role of gut microbiota in pancreatic disease: a systematic review. Pancreatology 17(6):867\u2013874. https:\/\/doi.org\/10.1016\/j.pan.2017.09.002","journal-title":"Pancreatology"},{"key":"4094_CR119","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jconrel.2015.08.017","volume":"219","author":"L Miao","year":"2015","unstructured":"Miao L, Lin CM, Huang L (2015) Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors. J Control Release 219:192\u2013204. https:\/\/doi.org\/10.1016\/j.jconrel.2015.08.017","journal-title":"J Control Release"},{"issue":"7","key":"4094_CR120","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/ueg2.12123","volume":"9","author":"P Michl","year":"2021","unstructured":"Michl P, Lohr M, Neoptolemos JP, Capurso G, Rebours V, Malats N, Ollivier M, Ricciardiello L (2021) UEG position paper on pancreatic cancer. Bringing pancreatic cancer to the 21st century: prevent, detect, and treat the disease earlier and better. United Eur Gastroenterol J 9(7):860\u2013871","journal-title":"United Eur Gastroenterol J"},{"issue":"1","key":"4094_CR121","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.canlet.2016.07.022","volume":"381","author":"S Midha","year":"2016","unstructured":"Midha S, Chawla S, Garg PK (2016) Modifiable and non-modifiable risk factors for pancreatic cancer: a review. Cancer Lett 381(1):269\u2013277. https:\/\/doi.org\/10.1016\/j.canlet.2016.07.022","journal-title":"Cancer Lett"},{"issue":"7","key":"4094_CR122","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1111\/cas.15377","volume":"113","author":"G Milano","year":"2022","unstructured":"Milano G, Innocenti F, Minami H (2022) Liposomal irinotecan (Onivyde): exemplifying the benefits of nanotherapeutic drugs. Cancer Sci 113(7):2224\u20132231. https:\/\/doi.org\/10.1111\/cas.15377","journal-title":"Cancer Sci"},{"issue":"3","key":"4094_CR123","doi-asserted-by":"publisher","first-page":"224","DOI":"10.5582\/bst.2024.01156","volume":"18","author":"H Momose","year":"2024","unstructured":"Momose H, Kudo S, Yoshida T, Hasui N, Matsuki R, Kogure M, Sakamoto Y (2024) Trends in the treatment of advanced pancreatic cancer. Biosci Trends 18(3):224\u2013232. https:\/\/doi.org\/10.5582\/bst.2024.01156","journal-title":"Biosci Trends"},{"issue":"3","key":"4094_CR124","doi-asserted-by":"publisher","first-page":"205","DOI":"10.29090\/psa.2020.03.019.0121","volume":"47","author":"B Morakul","year":"2020","unstructured":"Morakul B (2020) Self-nanoemulsifying drug delivery systems (SNEDDS): an advancement technology for oral drug delivery. Pharmaceutical Sci Asia 47(3):205\u2013220. https:\/\/doi.org\/10.29090\/psa.2020.03.019.0121","journal-title":"Pharmaceutical Sci Asia"},{"issue":"6","key":"4094_CR125","doi-asserted-by":"publisher","first-page":"59","DOI":"10.21037\/cco.2017.12.01","volume":"6","author":"ME Mostafa","year":"2017","unstructured":"Mostafa ME, Erbarut-Seven I, Pehlivanoglu B, Adsay V (2017) Pathologic classification of \u201cpancreatic cancers\u201d: current concepts and challenges. Chin Clin Oncol 6(6):59. https:\/\/doi.org\/10.21037\/cco.2017.12.01","journal-title":"Chin Clin Oncol"},{"issue":"8","key":"4094_CR126","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1080\/17425247.2018.1504018","volume":"15","author":"H Mu","year":"2018","unstructured":"Mu H, Holm R (2018) Solid lipid nanocarriers in drug delivery: characterization and design. Expert Opin Drug Deliv 15(8):771\u2013785. https:\/\/doi.org\/10.1080\/17425247.2018.1504018","journal-title":"Expert Opin Drug Deliv"},{"issue":"19","key":"4094_CR127","doi-asserted-by":"publisher","first-page":"19585","DOI":"10.18632\/aging.103918","volume":"12","author":"Y Mu","year":"2020","unstructured":"Mu Y, Wang D, Bie L, Luo S, Mu X, Zhao Y (2020) Glypican-1-targeted and gemcitabine-loaded liposomes enhance tumor-suppressing effect on pancreatic cancer. Aging (Albany NY) 12(19):19585\u201319596. https:\/\/doi.org\/10.18632\/aging.103918","journal-title":"Aging (Albany NY)"},{"issue":"4","key":"4094_CR128","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3797\/scipharm.1105-09","volume":"79","author":"BK Nanjwade","year":"2011","unstructured":"Nanjwade BK, Patel DJ, Udhani RA, Manvi FV (2011) Functions of lipids for enhancement of oral bioavailability of poorly water-soluble drugs. Sci Pharm 79(4):705\u2013727. https:\/\/doi.org\/10.3797\/scipharm.1105-09","journal-title":"Sci Pharm"},{"issue":"10","key":"4094_CR129","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.3390\/cancers16101808","volume":"16","author":"OT Olaoba","year":"2024","unstructured":"Olaoba OT, Adelusi TI, Yang M, Maidens T, Kimchi ET, Staveley-O\u2019Carroll KF, Li G (2024) Driver mutations in pancreatic cancer and opportunities for targeted therapy. Cancers (Basel) 16(10):1808. https:\/\/doi.org\/10.3390\/cancers16101808","journal-title":"Cancers (Basel)"},{"key":"4094_CR130","doi-asserted-by":"publisher","unstructured":"Oneda E, Zaniboni A (2019) Are we sure that adjuvant chemotherapy is the best approach for resectable pancreatic cancer? Are we in the era of neoadjuvant treatment? A review of current literature. J Clin Med, 8(11). https:\/\/doi.org\/10.3390\/jcm8111922","DOI":"10.3390\/jcm8111922"},{"issue":"1","key":"4094_CR131","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13014-019-1345-6","volume":"14","author":"M Orth","year":"2019","unstructured":"Orth M, Metzger P, Gerum S, Mayerle J, Schneider G, Belka C, Schnurr M, Lauber K (2019) Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat Oncol 14(1):141. https:\/\/doi.org\/10.1186\/s13014-019-1345-6","journal-title":"Radiat Oncol"},{"issue":"11","key":"4094_CR132","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nrd.2016.139","volume":"15","author":"JM Ostrem","year":"2016","unstructured":"Ostrem JM, Shokat KM (2016) Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. Nat Rev Drug Discov 15(11):771\u2013785. https:\/\/doi.org\/10.1038\/nrd.2016.139","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"4094_CR133","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.nantod.2012.01.002","volume":"7","author":"SC Owen","year":"2012","unstructured":"Owen SC, Chan DPY, Shoichet MS (2012) Polymeric micelle stability. Nano Today 7(1):53\u201365. https:\/\/doi.org\/10.1016\/j.nantod.2012.01.002","journal-title":"Nano Today"},{"issue":"3","key":"4094_CR134","doi-asserted-by":"publisher","first-page":"298","DOI":"10.5858\/arpa.2021-0399-RA","volume":"146","author":"K Ozcan","year":"2022","unstructured":"Ozcan K, Klimstra DS (2022) A review of mucinous cystic and intraductal neoplasms of the pancreatobiliary tract. Arch Pathol Lab Med 146(3):298\u2013311. https:\/\/doi.org\/10.5858\/arpa.2021-0399-RA","journal-title":"Arch Pathol Lab Med"},{"issue":"1\u20132","key":"4094_CR135","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ijpharm.2016.12.009","volume":"517","author":"K Ozturk","year":"2017","unstructured":"Ozturk K, Esendagli G, Gurbuz MU, Tulu M, Calis S (2017) Effective targeting of gemcitabine to pancreatic cancer through PEG-cored Flt-1 antibody-conjugated dendrimers. Int J Pharm 517(1\u20132):157\u2013167. https:\/\/doi.org\/10.1016\/j.ijpharm.2016.12.009","journal-title":"Int J Pharm"},{"issue":"9","key":"4094_CR136","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park W, Chawla A, O\u2019Reilly EM (2021) Pancreatic Cancer: a review. Jama 326(9):851\u2013862. https:\/\/doi.org\/10.1001\/jama.2021.13027","journal-title":"Jama"},{"issue":"1","key":"4094_CR137","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3390\/pharmaceutics16010095","volume":"16","author":"M Pereira-Silva","year":"2024","unstructured":"Pereira-Silva M, Miranda-Pastoriza D, Diaz-Gomez L, Sotelo E, Paiva-Santos AC, Veiga F, Concheiro A, Alvarez-Lorenzo C (2024) Gemcitabine-vitamin E prodrug-loaded micelles for pancreatic cancer therapy. Pharmaceutics 16(1):95. https:\/\/doi.org\/10.3390\/pharmaceutics16010095","journal-title":"Pharmaceutics"},{"key":"4094_CR138","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejpb.2015.03.018","volume":"93","author":"E Perez-Herrero","year":"2015","unstructured":"Perez-Herrero E, Fernandez-Medarde A (2015) Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm 93:52\u201379. https:\/\/doi.org\/10.1016\/j.ejpb.2015.03.018","journal-title":"Eur J Pharm Biopharm"},{"key":"4094_CR139","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10689-008-9214-8","volume":"8","author":"J Permuth-Wey","year":"2009","unstructured":"Permuth-Wey J, Egan KM (2009) Family history is a significant risk factor for pancreatic cancer: results from a systematic review and meta-analysis. Fam Cancer 8:109\u2013117","journal-title":"Fam Cancer"},{"issue":"8","key":"4094_CR140","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.pan.2018.07.009","volume":"18","author":"MLB Peters","year":"2018","unstructured":"Peters MLB, Eckel A, Mueller PP, Tramontano AC, Weaver DT, Lietz A, Hur C, Kong CY, Pandharipande PV (2018) Progression to pancreatic ductal adenocarcinoma from pancreatic intraepithelial neoplasia: results of a simulation model. Pancreatology 18(8):928\u2013934. https:\/\/doi.org\/10.1016\/j.pan.2018.07.009","journal-title":"Pancreatology"},{"key":"4094_CR141","doi-asserted-by":"publisher","unstructured":"Pfl\u00fcger MJ, No\u00eb M, Brosens LAA (2023) Pancreatic cancer. In The Pancreas (pp. 969\u2013981). https:\/\/doi.org\/10.1002\/9781119876007.ch126","DOI":"10.1002\/9781119876007.ch126"},{"issue":"20","key":"4094_CR142","doi-asserted-by":"publisher","first-page":"5018","DOI":"10.1158\/1078-0432.CCR-18-0531","volume":"24","author":"MJ Pishvaian","year":"2018","unstructured":"Pishvaian MJ, Bender RJ, Halverson D, Rahib L, Hendifar AE, Mikhail S, Chung V, Picozzi VJ, Sohal D, Blais EM, Mason K, Lyons EE, Matrisian LM, Brody JR, Madhavan S, Petricoin EF 3rd (2018) Molecular profiling of patients with pancreatic cancer: initial results from the Know Your Tumor Initiative. Clin Cancer Res 24(20):5018\u20135027. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0531","journal-title":"Clin Cancer Res"},{"key":"4094_CR143","doi-asserted-by":"publisher","first-page":"7133","DOI":"10.2147\/IJN.S436253","volume":"18","author":"G Qi","year":"2023","unstructured":"Qi G, Shi G, Wang S, Hu H, Zhang Z, Yin Q, Li Z, Hao L (2023) A novel pH-responsive iron oxide core-shell magnetic mesoporous silica nanoparticle (M-MSN) system encapsulating doxorubicin (DOX) and glucose oxidase (Gox) for pancreatic cancer treatment. Int J Nanomedicine 18:7133\u20137147. https:\/\/doi.org\/10.2147\/IJN.S436253","journal-title":"Int J Nanomedicine"},{"key":"4094_CR144","unstructured":"Randomized Phase II Study of NaliCap (Irinotecan Liposome\/Capecitabine) Compared to NAPOLI (Irinotecan Liposome\/5-fluorouracil\/Leucovorin) in Gemcitabine-pretreated Advanced Pancreatic Cancer. (2020). https:\/\/clinicaltrials.gov\/study\/NCT04371224"},{"issue":"1","key":"4094_CR145","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14740\/wjon1166","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P, Sunkara T, Gaduputi V (2019) Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol 10(1):10\u201327. https:\/\/doi.org\/10.14740\/wjon1166","journal-title":"World J Oncol"},{"issue":"4","key":"4094_CR146","doi-asserted-by":"publisher","first-page":"346","DOI":"10.2174\/1389200218666170201151135","volume":"18","author":"A Rebelo","year":"2017","unstructured":"Rebelo A, Molpeceres J, Rijo P, Reis CP (2017) Pancreatic cancer therapy review: from classic therapeutic agents to modern nanotechnologies. Curr Drug Metab 18(4):346\u2013359. https:\/\/doi.org\/10.2174\/1389200218666170201151135","journal-title":"Curr Drug Metab"},{"key":"4094_CR147","unstructured":"Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy: A Prospective, Randomized, Non-Inferiority Trial (2024). https:\/\/clinicaltrials.gov\/study\/NCT06411795"},{"key":"4094_CR148","doi-asserted-by":"publisher","unstructured":"Reddy MR, Gubbiyappa KS (2021) A comprehensive review on supersaturable self-nanoemulsifying drug delivery system. Asian J Pharmaceut Clin Res 40\u201344. https:\/\/doi.org\/10.22159\/ajpcr.2021.v14i8.41987","DOI":"10.22159\/ajpcr.2021.v14i8.41987"},{"issue":"8","key":"4094_CR149","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1097\/MPA.0000000000000879","volume":"46","author":"AP Rijkers","year":"2017","unstructured":"Rijkers AP, Bakker OJ, Ahmed Ali U, Hagenaars J, van Santvoort HC, Besselink MG, Bollen TL, van Eijck CH, Dutch Pancreatitis Study, G (2017) Risk of pancreatic cancer after a primary episode of acute pancreatitis. Pancreas 46(8):1018\u20131022. https:\/\/doi.org\/10.1097\/MPA.0000000000000879","journal-title":"Pancreas"},{"key":"4094_CR150","doi-asserted-by":"publisher","unstructured":"Riley RS, Day ES (2017) Gold nanoparticle-mediated photothermal therapy: applications and opportunities for multimodal cancer treatment. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 9(4). https:\/\/doi.org\/10.1002\/wnan.1449","DOI":"10.1002\/wnan.1449"},{"issue":"4","key":"4094_CR151","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3390\/cancers14040985","volume":"14","author":"S Robatel","year":"2022","unstructured":"Robatel S, Schenk M (2022) Current limitations and novel perspectives in pancreatic cancer treatment. Cancers (Basel) 14(4):985. https:\/\/doi.org\/10.3390\/cancers14040985","journal-title":"Cancers (Basel)"},{"issue":"3","key":"4094_CR152","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10689-024-00389-w","volume":"23","author":"NJ Rodriguez","year":"2024","unstructured":"Rodriguez NJ, Syngal S (2024) Expanding access to genetic testing for pancreatic cancer. Fam Cancer 23(3):247\u2013254. https:\/\/doi.org\/10.1007\/s10689-024-00389-w","journal-title":"Fam Cancer"},{"issue":"1","key":"4094_CR153","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12935-023-03115-1","volume":"23","author":"M Roshani","year":"2023","unstructured":"Roshani M, Rezaian-Isfahni A, Lotfalizadeh MH, Khassafi N, Abadi M, Nejati M (2023) Metal nanoparticles as apotential technique for the diagnosis and treatment of gastrointestinal cancer: a comprehensive review. Cancer Cell Int 23(1):280. https:\/\/doi.org\/10.1186\/s12935-023-03115-1","journal-title":"Cancer Cell Int"},{"issue":"3","key":"4094_CR154","doi-asserted-by":"publisher","first-page":"101","DOI":"10.31083\/j.fbl2903101","volume":"29","author":"SM Ruff","year":"2024","unstructured":"Ruff SM, Pawlik TM (2024) Molecular classification and pathogenesis of pancreatic adenocarcinoma and targeted therapies: a review. Front Biosci (Landmark Ed) 29(3):101. https:\/\/doi.org\/10.31083\/j.fbl2903101","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"11","key":"4094_CR155","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1056\/NEJMra1404198","volume":"371","author":"DP Ryan","year":"2014","unstructured":"Ryan DP, Hong TS, Bardeesy N (2014) Pancreatic adenocarcinoma. N Engl J Med 371(11):1039\u20131049. https:\/\/doi.org\/10.1056\/NEJMra1404198","journal-title":"N Engl J Med"},{"issue":"8","key":"4094_CR156","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s12032-024-02443-0","volume":"41","author":"MJ Saadh","year":"2024","unstructured":"Saadh MJ, Mustafa MA, Malathi H, Ahluwalia G, Kaur S, Al-Dulaimi M, Alubiady MHS, Zain Al-Abdeen SH, Shakier HG, Ali MS, Ahmad I, Abosaoda MK (2024) Targeting the pancreatic tumor microenvironment by plant-derived products and their nanoformulations. Med Oncol 41(8):201. https:\/\/doi.org\/10.1007\/s12032-024-02443-0","journal-title":"Med Oncol"},{"key":"4094_CR157","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/978-981-33-4497-6_10","volume-title":"Nanocarriers: Drug Delivery System","author":"GU Sailor","year":"2021","unstructured":"Sailor GU (2021) Self-nanoemulsifying drug delivery systems (SNEDDS): an innovative approach to improve oral bioavailability. In: Shah N (ed) Nanocarriers: Drug Delivery System. Springer Singapore, pp 255\u2013280. https:\/\/doi.org\/10.1007\/978-981-33-4497-6_10"},{"key":"4094_CR158","doi-asserted-by":"publisher","unstructured":"Samaan JS, Abboud Y, Oh J, Jiang Y, Watson R, Park K, Liu Q, Atkins K, Hendifar A, Gong J, Osipov A, Li D, Nissen NN, Pandol SJ, Lo SK, Gaddam S (2023) Pancreatic cancer incidence trends by race, ethnicity, age and sex in the United States: a population-based study, 2000\u20132018. Cancers (Basel), 15(3). https:\/\/doi.org\/10.3390\/cancers15030870","DOI":"10.3390\/cancers15030870"},{"issue":"7","key":"4094_CR159","first-page":"1149","volume":"5","author":"MK Sarangi","year":"2016","unstructured":"Sarangi MK, Padhi S (2016) Solid lipid nanoparticles\u2013a review. Drugs 5(7):1149","journal-title":"Drugs"},{"issue":"3","key":"4094_CR160","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3390\/polym15030708","volume":"15","author":"T Sato","year":"2023","unstructured":"Sato T (2023) Kinetics of micellization and liquid-liquid phase separation in dilute block copolymer solutions. Polym (Basel) 15(3):708. https:\/\/doi.org\/10.3390\/polym15030708","journal-title":"Polym (Basel)"},{"issue":"6","key":"4094_CR161","first-page":"385","volume":"4","author":"SK Savale","year":"2015","unstructured":"Savale SK (2015) A review-self nanoemulsifying drug delivery system (SNEDDS). Int J Res Pharmaceut Nano Sci 4(6):385\u2013397","journal-title":"Int J Res Pharmaceut Nano Sci"},{"key":"4094_CR162","doi-asserted-by":"publisher","unstructured":"Schepis T, De Lucia SS, Pellegrino A, Del Gaudio A, Maresca R, Coppola G, Chiappetta MF, Gasbarrini A, Franceschi F, Candelli M, Nista EC (2023) State-of-the-art and upcoming innovations in pancreatic cancer care: a step forward to precision medicine. Cancers (Basel), 15(13). https:\/\/doi.org\/10.3390\/cancers15133423","DOI":"10.3390\/cancers15133423"},{"key":"4094_CR163","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/978-1-4939-7193-0_37","volume-title":"pancreatic cancer","author":"F Sclafani","year":"2018","unstructured":"Sclafani F, Cunningham D, Okines A, Ratnayake G, Chau I (2018) Chemotherapy for advanced pancreatic cancer. In: Neoptolemos JP, Urrutia R, Abbruzzese JL, B\u00fcchler MW (eds) pancreatic cancer. Springer, New York, pp 875\u2013921. https:\/\/doi.org\/10.1007\/978-1-4939-7193-0_37"},{"key":"4094_CR164","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2019.05.007","volume":"77","author":"T Seufferlein","year":"2019","unstructured":"Seufferlein T, Hammel P, Delpero JR, Macarulla T, Pfeiffer P, Prager GW, Reni M, Falconi M, Philip PA, Van Cutsem E (2019) Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: expert opinion based on a review of current evidence. Cancer Treat Rev 77:1\u201310. https:\/\/doi.org\/10.1016\/j.ctrv.2019.05.007","journal-title":"Cancer Treat Rev"},{"key":"4094_CR165","doi-asserted-by":"publisher","first-page":"102479","DOI":"10.1016\/j.jddst.2021.102479","volume":"63","author":"H Shah","year":"2021","unstructured":"Shah H, Nair AB, Shah J, Jacob S, Bharadia P, Haroun M (2021) Proniosomal vesicles as an effective strategy to optimize naproxen transdermal delivery. J Drug Deliv Sci Technol 63:102479. https:\/\/doi.org\/10.1016\/j.jddst.2021.102479","journal-title":"J Drug Deliv Sci Technol"},{"issue":"12","key":"4094_CR166","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.3390\/pharmaceutics15122651","volume":"15","author":"VM Shah","year":"2023","unstructured":"Shah VM, Rizvi S, Smith A, Tsuda M, Krieger M, Pelz C, MacPherson K, Eng J, Chin K, Munks MW, Daniel CJ, Al-Fatease A, Yardimci GG, Langer EM, Brody JR, Sheppard BC, Alani AW, Sears RC (2023) Micelle-formulated juglone effectively targets pancreatic cancer and remodels the tumor microenvironment. Pharmaceutics 15(12):2651. https:\/\/doi.org\/10.3390\/pharmaceutics15122651","journal-title":"Pharmaceutics"},{"key":"4094_CR167","unstructured":"Shakya, V. K., & Bansal, B. K. (2014). Niosomes : a novel trend in drug delivery."},{"key":"4094_CR168","doi-asserted-by":"publisher","unstructured":"Sharma R, Ghosh R, Kumar S, Komal K, Kumar M (2025) Decoding pancreatic cancer: key risk factors across genetics and lifestyle. Expert Rev Mol Diagn, 1\u20135. https:\/\/doi.org\/10.1080\/14737159.2025.2464563","DOI":"10.1080\/14737159.2025.2464563"},{"issue":"05","key":"4094_CR169","doi-asserted-by":"publisher","first-page":"29","DOI":"10.31782\/ijcrr.2022.14511","volume":"14","author":"MC Shekhar","year":"2022","unstructured":"Shekhar MC, Sandhya P (2022) Development of irinotecan dissolution rate by SNEDDS. Int J Curr Res Rev 14(05):29\u201336. https:\/\/doi.org\/10.31782\/ijcrr.2022.14511","journal-title":"Int J Curr Res Rev"},{"issue":"5","key":"4094_CR170","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1615\/critrevtherdrugcarriersyst.v26.i5.10","volume":"26","author":"B Singh","year":"2009","unstructured":"Singh B, Bandopadhyay S, Kapil R, Singh R, Katare O (2009) Self-emulsifying drug delivery systems (SEDDS): formulation development, characterization, and applications. Crit Rev Ther Drug Carrier Syst 26(5):427\u2013521. https:\/\/doi.org\/10.1615\/critrevtherdrugcarriersyst.v26.i5.10","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"4094_CR171","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/b978-0-323-41533-0.00004-0","volume-title":"Fabrication and Self-Assembly of Nanobiomaterials","author":"B Singh","year":"2016","unstructured":"Singh B, Garg B, Kaur R, Jain A, Kumar R, Katare OP (2016) Self-nanoemulsifying systems for oral bioavailability enhancement. In: Grumezescu AM (ed) Fabrication and Self-Assembly of Nanobiomaterials. William Andrew Publishing, pp 91\u2013115. https:\/\/doi.org\/10.1016\/b978-0-323-41533-0.00004-0"},{"issue":"7","key":"4094_CR172","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.3390\/ijms19071979","volume":"19","author":"P Singh","year":"2018","unstructured":"Singh P, Pandit S, Mokkapati V, Garg A, Ravikumar V, Mijakovic I (2018) Gold nanoparticles in diagnostics and therapeutics for human cancer. Int J Mol Sci 19(7):1979. https:\/\/doi.org\/10.3390\/ijms19071979","journal-title":"Int J Mol Sci"},{"key":"4094_CR173","unstructured":"Single-arm, Open-label Clinical Study of Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-Fluorouracil\/Leucovorin (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer After First-line Therapy Failure With AG Regimen. (2024). https:\/\/clinicaltrials.gov\/study\/NCT06538623"},{"issue":"7","key":"4094_CR174","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.3390\/ijms24076199","volume":"24","author":"D Sivadasan","year":"2023","unstructured":"Sivadasan D, Ramakrishnan K, Mahendran J, Ranganathan H, Karuppaiah A, Rahman H (2023) Solid lipid nanoparticles: applications and prospects in cancer treatment. Int J Mol Sci 24(7):6199. https:\/\/doi.org\/10.3390\/ijms24076199","journal-title":"Int J Mol Sci"},{"key":"4094_CR175","unstructured":"Spleen Irradiation With Nanoliposomal Irinotecan Plus 5-FU and Leucovorin in Metastatic Pancreatic Adenocarcinoma: a Phase II Study (SINAI). (2022). https:\/\/clinicaltrials.gov\/study\/NCT05363007"},{"issue":"3 Pt 2","key":"4094_CR176","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/j.lpm.2019.02.025","volume":"48","author":"C Springfeld","year":"2019","unstructured":"Springfeld C, Jager D, Buchler MW, Strobel O, Hackert T, Palmer DH, Neoptolemos JP (2019) Chemotherapy for pancreatic cancer. Presse Med 48(3 Pt 2):e159\u2013e174. https:\/\/doi.org\/10.1016\/j.lpm.2019.02.025","journal-title":"Presse Med"},{"issue":"4","key":"4094_CR177","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.3390\/cimb46040177","volume":"46","author":"D Stefanoudakis","year":"2024","unstructured":"Stefanoudakis D, Frountzas M, Schizas D, Michalopoulos NV, Drakaki A, Toutouzas KG (2024) Significance of TP53, CDKN2A, SMAD4 and KRAS in pancreatic cancer. Curr Issues Mol Biol 46(4):2827\u20132844. https:\/\/doi.org\/10.3390\/cimb46040177","journal-title":"Curr Issues Mol Biol"},{"issue":"5","key":"4094_CR178","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/nrgastro.2017.12","volume":"14","author":"P Storz","year":"2017","unstructured":"Storz P (2017) Acinar cell plasticity and development of pancreatic ductal adenocarcinoma. Nat Rev Gastroenterol Hepatol 14(5):296\u2013304. https:\/\/doi.org\/10.1038\/nrgastro.2017.12","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"4094_CR179","doi-asserted-by":"publisher","first-page":"523","DOI":"10.7150\/thno.17259","volume":"7","author":"J Su","year":"2017","unstructured":"Su J, Sun H, Meng Q, Zhang P, Yin Q, Li Y (2017) Enhanced blood suspensibility and laser-activated tumor-specific drug release of theranostic mesoporous silica nanoparticles by functionalizing with erythrocyte membranes. Theranostics 7(3):523\u2013537. https:\/\/doi.org\/10.7150\/thno.17259","journal-title":"Theranostics"},{"key":"4094_CR180","doi-asserted-by":"publisher","first-page":"116754","DOI":"10.1016\/j.lfs.2019.116754","volume":"233","author":"FS Tabatabaei Mirakabad","year":"2019","unstructured":"Tabatabaei Mirakabad FS, Khoramgah MS, Keshavarz FK, Tabarzad M, Ranjbari J (2019) Peptide dendrimers as valuable biomaterials in medical sciences. Life Sci 233:116754. https:\/\/doi.org\/10.1016\/j.lfs.2019.116754","journal-title":"Life Sci"},{"issue":"12","key":"4094_CR181","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.3390\/cells12121586","volume":"12","author":"HKC Tang","year":"2023","unstructured":"Tang HKC, Wang B, Tan HX, Sarwar MA, Baraka B, Shafiq T, Rao AR (2023) CAR T-Cell therapy for cancer: latest updates and challenges, with a focus on B-lymphoid malignancies and selected solid tumours. Cells 12(12):1586. https:\/\/doi.org\/10.3390\/cells12121586","journal-title":"Cells"},{"key":"4094_CR182","doi-asserted-by":"publisher","unstructured":"Tesson M, Morton JP (2024) The preclinical gap in pancreatic cancer and radiotherapy. Dis Model Mech, 17(7). https:\/\/doi.org\/10.1242\/dmm.050703","DOI":"10.1242\/dmm.050703"},{"key":"4094_CR183","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.2147\/IJN.S106736","volume":"11","author":"A Thakkar","year":"2016","unstructured":"Thakkar A, Chenreddy S, Thio A, Khamas W, Wang J, Prabhu S (2016) Preclinical systemic toxicity evaluation of chitosan-solid lipid nanoparticle-encapsulated aspirin and curcumin in combination with free sulforaphane in BALB\/c mice. Int J Nanomedicine 11:3265\u20133276. https:\/\/doi.org\/10.2147\/IJN.S106736","journal-title":"Int J Nanomedicine"},{"issue":"02","key":"4094_CR184","first-page":"81","volume":"4","author":"S Tiwari","year":"2012","unstructured":"Tiwari S, Upadhyay R (2012) Fighting pancreatic cancer: from bench to bedside using solid lipid nanoparticle. Indian Res J Genetics Biotechnol 4(02):81\u201385","journal-title":"Indian Res J Genetics Biotechnol"},{"issue":"2\u20133","key":"4094_CR185","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/s0168-3659(01)00299-1","volume":"73","author":"VP Torchilin","year":"2001","unstructured":"Torchilin VP (2001) Structure and design of polymeric surfactant-based drug delivery systems. J Control Release 73(2\u20133):137\u2013172. https:\/\/doi.org\/10.1016\/s0168-3659(01)00299-1","journal-title":"J Control Release"},{"key":"4094_CR186","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-642-00477-3_1","volume":"197","author":"VP Torchilin","year":"2010","unstructured":"Torchilin VP (2010) Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol 197:3\u201353. https:\/\/doi.org\/10.1007\/978-3-642-00477-3_1","journal-title":"Handb Exp Pharmacol"},{"key":"4094_CR187","unstructured":"Torgerson S, Wiebe LA (2013) Supportive care of the patient with advanced pancreatic cancer. Oncology (Williston Park), 27(3):183\u2013190. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23687787"},{"key":"4094_CR188","doi-asserted-by":"crossref","unstructured":"Upponi JR, Torchilin VP (2014) Passive vs. active targeting: an update of the epr role in drug delivery to tumors. In Nano-Oncologicals: New Targeting and Delivery Approaches (pp. 3\u201345). Springer.","DOI":"10.1007\/978-3-319-08084-0_1"},{"issue":"9","key":"4094_CR189","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41551-021-00698-w","volume":"5","author":"AM Vargason","year":"2021","unstructured":"Vargason AM, Anselmo AC, Mitragotri S (2021) The evolution of commercial drug delivery technologies. Nat Biomed Eng 5(9):951\u2013967. https:\/\/doi.org\/10.1038\/s41551-021-00698-w","journal-title":"Nat Biomed Eng"},{"issue":"9","key":"4094_CR190","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.3390\/pharmaceutics15092363","volume":"15","author":"C Viegas","year":"2023","unstructured":"Viegas C, Patricio AB, Prata J, Fonseca L, Macedo AS, Duarte SOD, Fonte P (2023) Advances in pancreatic cancer treatment by nano-based drug delivery systems. Pharmaceutics 15(9):2363. https:\/\/doi.org\/10.3390\/pharmaceutics15092363","journal-title":"Pharmaceutics"},{"issue":"12","key":"4094_CR191","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.2217\/nnm-2018-0114","volume":"13","author":"MK Viswanadh","year":"2018","unstructured":"Viswanadh MK, Muthu MS (2018) Targeted bioadhesive nanomedicine: an effective approach for synergistic drug delivery to cancers. Nanomedicine (Lond) 13(12):1401\u20131403. https:\/\/doi.org\/10.2217\/nnm-2018-0114","journal-title":"Nanomedicine (Lond)"},{"key":"4094_CR192","doi-asserted-by":"publisher","DOI":"10.1002\/9783527626953","volume-title":"Dendrimer chemistry: concepts, syntheses, properties, applications","author":"F V\u00f6gtle","year":"2009","unstructured":"V\u00f6gtle F, Richardt G, Werner N (2009) Dendrimer chemistry: concepts, syntheses, properties, applications. John Wiley & Sons"},{"issue":"4","key":"4094_CR193","doi-asserted-by":"publisher","first-page":"239","DOI":"10.4149\/BLL_2024_36","volume":"125","author":"M Vojtko","year":"2024","unstructured":"Vojtko M, Cmarkova K, Pindura M, Palkoci B, Kycina R, Nosakova L, Vojtko M, Banovcin P, Miklusica J (2024) Distal pancreatectomy. Bratisl Lek Listy 125(4):239\u2013243. https:\/\/doi.org\/10.4149\/BLL_2024_36","journal-title":"Bratisl Lek Listy"},{"issue":"18","key":"4094_CR194","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Renschler MF (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691\u20131703. https:\/\/doi.org\/10.1056\/NEJMoa1304369","journal-title":"N Engl J Med"},{"issue":"7540","key":"4094_CR195","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature14169","volume":"518","author":"N Waddell","year":"2015","unstructured":"Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, Quinn MC, Robertson AJ, Fadlullah MZ, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Grimmond SM (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518(7540):495\u2013501. https:\/\/doi.org\/10.1038\/nature14169","journal-title":"Nature"},{"key":"4094_CR196","doi-asserted-by":"publisher","first-page":"101876","DOI":"10.1016\/j.pdpdt.2020.101876","volume":"31","author":"Y Wang","year":"2020","unstructured":"Wang Y, Wang H, Zhou L, Lu J, Jiang B, Liu C, Guo J (2020) Photodynamic therapy of pancreatic cancer: where have we come from and where are we going? Photodiagnosis Photodyn Ther 31:101876. https:\/\/doi.org\/10.1016\/j.pdpdt.2020.101876","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"4094_CR197","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.actbio.2021.10.048","volume":"138","author":"M Wang","year":"2022","unstructured":"Wang M, Li Y, Wang M, Liu K, Hoover AR, Li M, Towner RA, Mukherjee P, Zhou F, Qu J, Chen WR (2022a) Synergistic interventional photothermal therapy and immunotherapy using an iron oxide nanoplatform for the treatment of pancreatic cancer. Acta Biomater 138:453\u2013462. https:\/\/doi.org\/10.1016\/j.actbio.2021.10.048","journal-title":"Acta Biomater"},{"key":"4094_CR198","unstructured":"Wang Z, Zhou Y, Jiang C, Song X, Miao Y, Zhang Y, Chen X, Zhu X (2019) Pancreatic cancer double-targeted polymer magnetic nanoparticles and preparation method and application thereof (CN Patent No. CN 109395102 A). https:\/\/lens.org\/030-494-862-690-49X"},{"key":"4094_CR199","unstructured":"Wang Y, Peng D, Tan C, Li M, Tang J, Xu H (2022) Preparation and application of fucoidan gemcitabine liposome targeting pancreatic cancer (CN Patent No. CN 115040658 A). https:\/\/lens.org\/070-382-446-962-788"},{"key":"4094_CR200","unstructured":"Wang H, Wang F, Zhang JUN, Shi FEI, Gu Z (2023). Application of irinotecan liposome combined with 5-fluorouracil and calcium folinate in preparation of medicine for treating pancreatic cancer (CN Patent No. CN 117159550 A). https:\/\/lens.org\/199-619-924-665-157"},{"issue":"5","key":"4094_CR201","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3322\/caac.21190","volume":"63","author":"CL Wolfgang","year":"2013","unstructured":"Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, Hruban RH (2013) Recent progress in pancreatic cancer. CA Cancer J Clin 63(5):318\u2013348. https:\/\/doi.org\/10.3322\/caac.21190","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"4094_CR202","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1093\/jnci\/djp020","volume":"101","author":"BM Wolpin","year":"2009","unstructured":"Wolpin BM, Chan AT, Hartge P, Chanock SJ, Kraft P, Hunter DJ, Giovannucci EL, Fuchs CS (2009) ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst 101(6):424\u2013431. https:\/\/doi.org\/10.1093\/jnci\/djp020","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"4094_CR203","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40291-013-0043-6","volume":"17","author":"LD Wood","year":"2013","unstructured":"Wood LD (2013) Pancreatic cancer genomes: toward molecular subtyping and novel approaches to diagnosis and therapy. Mol Diagn Ther 17(5):287\u2013297. https:\/\/doi.org\/10.1007\/s40291-013-0043-6","journal-title":"Mol Diagn Ther"},{"key":"4094_CR204","doi-asserted-by":"publisher","unstructured":"Wood LD, Canto MI, Jaffee EM, Simeone DM (2022) Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment. Gastroenterology 163(2):386\u2013402 e381. https:\/\/doi.org\/10.1053\/j.gastro.2022.03.056","DOI":"10.1053\/j.gastro.2022.03.056"},{"key":"4094_CR205","doi-asserted-by":"crossref","unstructured":"Xu X, Tian F, Pan Y, Zhang T, Deng L, Jiang H, Han J, Liu J, Zhao Y, Liu W (2025) Emerging mechanistic insights into liposomal stability: full process management from production and storage to food application. Chem Eng J 159552.","DOI":"10.1016\/j.cej.2025.159552"},{"issue":"1","key":"4094_CR206","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00595-017-1501-2","volume":"48","author":"J Yamaguchi","year":"2018","unstructured":"Yamaguchi J, Yokoyama Y, Kokuryo T, Ebata T, Nagino M (2018) Cells of origin of pancreatic neoplasms. Surg Today 48(1):9\u201317. https:\/\/doi.org\/10.1007\/s00595-017-1501-2","journal-title":"Surg Today"},{"key":"4094_CR207","doi-asserted-by":"publisher","unstructured":"Yazdian-Robati R, Ahmadi SM, Mavandadnejad F, Ebrahimnejad P, Amirkhanloo S, Shad A (2024) Chapter 5 - Liposome- and niosome-based drug delivery for pancreatic cancer. In: Kesharwani P, Gupta N (eds) Recent advances in nanocarriers for pancreatic cancer therapy. Academic Press. pp 95\u2013114. https:\/\/doi.org\/10.1016\/B978-0-443-19142-8.00014-0","DOI":"10.1016\/B978-0-443-19142-8.00014-0"},{"issue":"29","key":"4094_CR208","doi-asserted-by":"publisher","first-page":"6081","DOI":"10.1039\/c5tb00587f","volume":"3","author":"F Yin","year":"2015","unstructured":"Yin F, Zhang B, Zeng S, Lin G, Tian J, Yang C, Wang K, Xu G, Yong KT (2015) Folic acid-conjugated organically modified silica nanoparticles for enhanced targeted delivery in cancer cells and tumor in vivo. J Mater Chem B 3(29):6081\u20136093. https:\/\/doi.org\/10.1039\/c5tb00587f","journal-title":"J Mater Chem B"},{"key":"4094_CR209","doi-asserted-by":"publisher","first-page":"102125","DOI":"10.1016\/j.cis.2020.102125","volume":"278","author":"M Yousefi","year":"2020","unstructured":"Yousefi M, Narmani A, Jafari SM (2020) Dendrimers as efficient nanocarriers for the protection and delivery of bioactive phytochemicals. Adv Colloid Interface Sci 278:102125. https:\/\/doi.org\/10.1016\/j.cis.2020.102125","journal-title":"Adv Colloid Interface Sci"},{"issue":"8","key":"4094_CR210","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1158\/1078-0432.CCR-22-2531","volume":"29","author":"C Zhang","year":"2023","unstructured":"Zhang C, Al-Shaheri FN, Alhamdani MSS, Bauer AS, Hoheisel JD, Schenk M, Hinz U, Goedecke P, Al-Halabi K, Buchler MW, Giese NA, Hackert T, Roth S (2023a) Blood-based diagnosis and risk stratification of patients with pancreatic intraductal papillary mucinous neoplasm (IPMN). Clin Cancer Res 29(8):1535\u20131545. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2531","journal-title":"Clin Cancer Res"},{"issue":"24","key":"4094_CR211","doi-asserted-by":"publisher","first-page":"e2301759","DOI":"10.1002\/advs.202301759","volume":"10","author":"G Zhang","year":"2023","unstructured":"Zhang G, Zhan M, Zhang C, Wang Z, Sun H, Tao Y, Shi Q, He M, Wang H, Rodrigues J, Shen M, Shi X (2023b) Redox-responsive dendrimer nanogels enable ultrasound-enhanced chemoimmunotherapy of pancreatic cancer via endoplasmic reticulum stress amplification and macrophage polarization. Adv Sci (Weinh) 10(24):e2301759. https:\/\/doi.org\/10.1002\/advs.202301759","journal-title":"Adv Sci (Weinh)"},{"issue":"2","key":"4094_CR212","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1166\/mex.2024.2600","volume":"14","author":"M Zhang","year":"2024","unstructured":"Zhang M, Gao F, Zhao X, Qi Y, Zhang L, Cao Y, Wang Y, Wang Y (2024) Nanocarrier-mediated co-delivery of gemcitabine and Bcl-2 siRNA for pancreatic cancer therapy. Mater Express 14(2):270\u2013277","journal-title":"Mater Express"},{"key":"4094_CR213","doi-asserted-by":"publisher","first-page":"153303382096211","DOI":"10.1177\/1533033820962117","volume":"19","author":"Z Zhao","year":"2020","unstructured":"Zhao Z, Liu W (2020) Pancreatic cancer: a review of risk factors, diagnosis, and treatment. Technol Cancer Res Treat 19:1533033820962117. https:\/\/doi.org\/10.1177\/1533033820962117","journal-title":"Technol Cancer Res Treat"},{"key":"4094_CR214","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.2147\/IJN.S371775","volume":"17","author":"W Zhao","year":"2022","unstructured":"Zhao W, Yang S, Li C, Li F, Pang H, Xu G, Wang Y, Cong M (2022) Amphiphilic dendritic nanomicelle-mediated delivery of gemcitabine for enhancing the specificity and effectiveness. Int J Nanomedicine 17:3239\u20133249. https:\/\/doi.org\/10.2147\/IJN.S371775","journal-title":"Int J Nanomedicine"},{"key":"4094_CR215","doi-asserted-by":"publisher","first-page":"122844","DOI":"10.1016\/j.ijpharm.2023.122844","volume":"636","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Zheng Y, Zhu Y, Ding K, Zhou M, Liu T (2023) Co-delivery of gemcitabine and triapine by calcium carbonate nanoparticles against chemoresistant pancreatic cancer. Int J Pharm 636:122844. https:\/\/doi.org\/10.1016\/j.ijpharm.2023.122844","journal-title":"Int J Pharm"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04094-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04094-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04094-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T04:39:17Z","timestamp":1758256757000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04094-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":215,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["4094"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04094-y","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"7 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}